SyMRI to be studied as a technology to characterize brain tumors

SyntheticMR and The University of Texas MD Anderson Cancer Center have signed a research agreement to study SyMRI to characterize brain tumors.

Photo: SyMRI to be studied as a technology to characterize brain tumors

SyMRI provides quantitative information including tissue segmentation and T1, T2 and PD-maps, thus adding objective data to the MRI exam. The technology will be studied for its potential to add diagnostic value for various clinical applications including characterization of brain tumors.

SyMRI IMAGE generates multiple contrast images from a single 3 to 6 minutes scan, thus allowing a significant reduction in scan time compared to serial acquisition of each contrast image separately. Parameters are also adjustable post scan, enabling both fine tuning of images as well as recreation of additional contrasts.  SyMRI NEURO adds quantitative data and automatic segmentation of brain tissue for efficient analysis and objective decision making. The agreement with MD Anderson includes a license of SyMRI IMAGE and SyMRI NEURO for research use at the hospital. SyMRI is CE-marked for clinical use in Europe but SyMRI is not available for clinical use in the USA.


Source: SyMRI

24.11.2015

Read all latest stories

Related articles

Photo

Aggressive brain tumour

Glioblastoma can be tricked into 'repairing' itself

Scientists at the University College London (UCL) have made a ‘surprising’ discovery that glioblastoma, an aggressive brain cancer, mimics normal brain repair in white matter, which leads to the…

Photo

Brain tumour analysis

Glioblastoma '3D maps' help find new therapies

Researchers at the Universitat Autònoma de Barcelona obtained a highly accurate recreation of human glioblastoma’s features using a novel 3D microscopy analysis. The study, published in the…

Photo

Brain tumor treatment network

'Federated learning' AI approach allows hospitals to share patient data privately

To answer medical questions that can be applied to a wide patient population, machine learning models rely on large, diverse datasets from a variety of institutions. However, health systems and…

Related products

mediaire – mdbrain

Artificial Intelligence

mediaire – mdbrain

mediaire GmbH
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Subscribe to Newsletter